Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion
Diabetes Care · 2026
DOI: 10.2337/dc25-2294 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2026. Verfasst von Jennifer K Leohr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN. Hauptthemen laut MEDLINE: Insulin Lispro, Diabetes Mellitus, Type 1, Exercise, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To compare the glycemic response and pharmacokinetics (PK) of ultra-rapid lispro (URLi) versus lispro during manual basal rate reductions (BRRs) before exercise with conventional continuous subcutaneous insulin infusion (CSII) in active adults with type 1 diabetes. RESEARCH DESIGN AND METHODS This study was a double-blind, four-period, crossover, randomized controlled trial. Exercise (60 min walking at 45–55% VO2max) was performed 4 h after a standardized meal, with either a 50% (−60 min) or 100% (−15 min) BRR before exercise using URLi or lispro. The primary end point was the change in glucose during exercise, and insulin lispro PK was the secondary end point. RESULTS Twenty-five participants (mean ± SD age 36.7 ± 10.3 years; mean ± SD HbA1c 50.4 ± 8.5 mmol/mol [6.76 ± 0.8%]; 48% female) completed the study. URLi significantly attenuated the reduction in glucose level compared with lispro during both the 50% BRR (−26.8 ± 37 vs. −39.0 ± 39 mg/dL; P < 0.05) and the 100% BRR (−46.9 ± 32 vs. −60.5 ± 39 mg/dL; P < 0.01). Circulating insulin lispro concentrations rose in the first 15 min of exercise, but maximum concentration was lower with URLi versus lispro within each BRR strategy. Numerically less hypoglycemia was observed during exercise with URLi (6%) compared with lispro (16%). Following a postexercise meal, faster insulin absorption of URLi resulted in an earlier postprandial glucose lowering compared with lispro. CONCLUSIONS Using URLi in conventional CSII pump therapy provides more effective BRRs prior to exercise compared with lispro, with fewer hypoglycemic events in active adults with type 1 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, IN.
- LMC Diabetes and Endocrinology, Toronto, Ontario, Canada.
- Muscle Health Research Centre, York University, Toronto, Ontario, Canada.
ORCID-Profile: Jennifer K Leohr
Förderung
- Eli Lilly and Company
Zitieren
APA
Leohr, J. K., Abitbol, A., Turner, L. V., Smith LaBell, E., Ghosh, A., Coutant, D. E., & Riddell, M. C. (2026). Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. Diabetes Care. https://doi.org/10.2337/dc25-2294
Vancouver
Leohr JK, Abitbol A, Turner LV, Smith LaBell E, Ghosh A, Coutant DE, et al. Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion. Diabetes Care. 2026. doi:10.2337/dc25-2294
BibTeX
@article{Leohr2026,
author = {Leohr, Jennifer K and Abitbol, Alexander and Turner, Lauren V and Smith LaBell, Elizabeth and Ghosh, Aritra and Coutant, David E and Riddell, Michael C},
title = {Ultra-Rapid Lispro Has an Improved Pharmacokinetic Profile for Exercise Compared With Lispro, Resulting in Less Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes on Open-Loop Continuous Subcutaneous Insulin Infusion},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc25-2294}
}
EUVIMED